Submission of Audited Financial Results (Standalone and Consolidated) along with Audit Report for the Quarter and Financial Year ended 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 1.1 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shree Pacetronix Ltd submitted its audited financial results for Q4 FY25 and the full year ended March 31, 2025. Standalone revenue from operations fell to Rs. 1,680.32 lakhs from Rs. 2,204.05 lakhs a year earlier, a drop of roughly 24%. Profit after tax shrank sharply to Rs. 75.30 lakhs from Rs. 335.83 lakhs (down around 78%), with basic EPS dropping to Rs. 2.09 from Rs. 9.33. The auditor issued a Qualified Opinion (a first-time qualification) on both standalone and consolidated results, flagging uncertainty over the recoverability of an Rs. 80 lakh investment in subsidiary Shree Coratomic Limited, whose Cochlear Implant project has been suspended for two years. Consolidated operating cash flow was almost flat at Rs. (0.79) lakhs, and the company operates in a single segment — Life Saving Devices (cardiac pacemakers).
The steep profit fall, single-segment concentration, and a first-time auditor qualification on a dormant subsidiary project may dent investor confidence and put pressure on the stock. Weak cash generation from core operations adds to the cautious near-term outlook for shareholders.